We confirmed that CHK1 inhibition has different effects on ER-/PR-/HER2- breast cancer than on ER+/PR+/HER2- breast cancer in the aspects of proliferation, apoptosis and ADR chemosensitivity. Here, ERBB2 is linked to breast cancer.